Stay updated with breaking news from 64026810. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has received an average rating of “Hold” from the five research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the […]
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The average […]
Primecap Management Co. CA trimmed its stake in Nektar Therapeutics (NASDAQ:NKTR – Free Report) by 11.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,197,983 shares of the biopharmaceutical company’s stock after selling 951,893 shares during the period. Primecap Management […]
Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Equities research analysts at Zacks Research lowered their FY2023 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, January 23rd. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.85) for […]
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 5,350,000 shares, a decrease of 23.1% from the December 15th total of 6,960,000 shares. Based on an average trading volume of 1,560,000 shares, the short-interest ratio is […]